New Delhi: Piramal Pharma Limited (PPL), a subsidiary of Piramal Enterprises Limited has received INR 3523.40 Crores on the closure of the transaction for 20% equity investment from CA Alchemy Investments (formerly known as CA Clover Intermediate II Investments), an affiliated entity of CAP V Mauritius Limited, an investment fund managed and advised by affiliated entities of The Carlyle Group Inc. (“Carlyle”). The transaction values the Pharma Business at an enterprise value (EV) of US$2,775 million with an upside component of up to US$360 million depending on the company’s FY21 performance. This transaction is one of the largest private equity deals in the Indian pharmaceutical sector. It provides PPL growth capital that enables it to invest in accelerated business growth through both organic and inorganic opportunities.
PPL’s business now effectively includes:
Piramal Pharma Solutions, an end-to-end contract development and manufacturing (CDMO) business
Piramal Critical Care, a complex hospital generics business selling specialized products across over 100 countries
Consumer Products Division, a consumer healthcare business selling over-the-counter products in India
PEL’s investment in the joint venture with Allergan India, a leader in ophthalmology in the domestic market and Convergence Chemicals Private Limited.